تیبولون (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "تیبولون" in Persian language version.

refsWebsite
Global rank Persian rank
3rd place
6th place
2nd place
2nd place
4th place
5th place
low place
low place
11th place
52nd place
1st place
1st place
low place
low place
low place
low place
3,823rd place
1,188th place
274th place
506th place
399th place
104th place
9,568th place
low place

books.google.com

doi.org

  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Albertazzi P, Di Micco R, Zanardi E (1998). "Tibolone: a review". Maturitas. 30 (3): 295–305. doi:10.1016/S0378-5122(98)00059-0. PMID 9881330.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (2009). "Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites". J. Steroid Biochem. Mol. Biol. 116 (1–2): 8–14. doi:10.1016/j.jsbmb.2009.03.008. PMID 19464167. S2CID 18346113.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • de Vries CS, Bromley SE, Thomas H, Farmer RD (2005). "Tibolone and endometrial cancer: a cohort and nested case-control study in the UK". Drug Safety. 28 (3): 241–9. doi:10.2165/00002018-200528030-00005. PMID 15733028. S2CID 19872216.

drugs.com

hormonebalance.org

  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.

hres.ca

hpr-rps.hres.ca

inserm.fr

hal.inserm.fr

medicines.org.uk

mhra.gov.uk

  • "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original (PDF) on 25 April 2018. Retrieved 4 July 2022.
  • "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original (PDF) on 25 April 2018. Retrieved 4 July 2022.
  • "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original (PDF) on 25 April 2018. Retrieved 4 July 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Albertazzi P, Di Micco R, Zanardi E (1998). "Tibolone: a review". Maturitas. 30 (3): 295–305. doi:10.1016/S0378-5122(98)00059-0. PMID 9881330.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T (2009). "Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites". J. Steroid Biochem. Mol. Biol. 116 (1–2): 8–14. doi:10.1016/j.jsbmb.2009.03.008. PMID 19464167. S2CID 18346113.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  • de Vries CS, Bromley SE, Thomas H, Farmer RD (2005). "Tibolone and endometrial cancer: a cohort and nested case-control study in the UK". Drug Safety. 28 (3): 241–9. doi:10.2165/00002018-200528030-00005. PMID 15733028. S2CID 19872216.

semanticscholar.org

api.semanticscholar.org

springer.com

adisinsight.springer.com

web.archive.org

  • "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original (PDF) on 25 April 2018. Retrieved 4 July 2022.
  • "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original (PDF) on 25 April 2018. Retrieved 4 July 2022.
  • "Tibolone 2.5 mg Tablets" (PDF). Public Assessment Report. United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original (PDF) on 25 April 2018. Retrieved 4 July 2022.